文献速递慢性肾脏病遗传性与小管间质肾病

罕见遗传性肾脏疾病的靶向基因治疗

Targeted gene therapy for rare genetic kidney diseases.
PubMed 文献 · Kidney Int · 2024-08-31

慢性肾脏病是全球主要死亡原因之一,约三分之一的病例与遗传性单基因因素相关,适合基因治疗干预。该综述探讨了靶向基因治疗在罕见遗传性肾脏疾病中的进展,包括病毒与非病毒载体的体内递送、小核酸药物以及造血干/祖细胞作为体外基因治疗载体的应用,并展望了临床应用前景。

要点

  • 约三分之一慢性肾脏病与遗传性单基因因素相关,是基因治疗的潜在靶点。
  • 肾脏复杂解剖结构限制靶向基因递送效率,需优化载体与递送途径。
  • 造血干/祖细胞可在肾脏内分化为巨噬细胞,通过隧道纳米管递送遗传物质。

核心结论

  • 基因治疗技术进展有望使遗传性肾脏病患者最终避免肾移植。

研究设计与样本

  • 综述,探讨靶向基因治疗在罕见遗传性肾脏疾病中的临床前研究与临床应用前景。

主要发现

  • 体内基因治疗最常用于肾脏靶向递送,通过全身、肾静脉和肾动脉注射给予病毒与非病毒载体。
  • 小核酸已在临床前和临床研究中用于治疗某些肾脏疾病。
  • 造血干/祖细胞作为体外基因治疗载体,在肾脏内分化为巨噬细胞,形成隧道纳米管向邻近肾细胞乃至跨基底膜向前端小管细胞递送遗传物质和细胞器。

临床怎么用

  • 关注靶向递送途径(全身、肾静脉、肾动脉)与载体选择对肾脏基因治疗效率的影响。
  • 关注造血干/祖细胞作为体外基因治疗载体在肾脏递送中的应用潜力。

局限性

  • 肾脏复杂解剖结构限制靶向基因递送至肾脏系统的有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease is one of the leading causes of mortality worldwide because of kidney failure and the associated challenges of its treatment including dialysis and kidney transplantation. About one-third of chronic kidney disease cases are linked to inherited monogenic factors, making them suitable for potential gene therapy interventions. However, the intricate anatomical structure of the kidney poses a challenge, limiting the effectiveness of targeted gene delivery to the renal system. In this review, we explore the progress made in the field of targeted gene therapy approaches and their implications for rare genetic kidney disorders, examining preclinical studies and prospects for clinical application. In vivo gene therapy is most commonly used for kidney-targeted gene delivery and involves administering viral and nonviral vectors through various routes such as systemic, renal vein, and renal arterial injections. Small nucleic acids have also been used in preclinical and clinical studies for treating certain kidney disorders. Unexpectedly, hematopoietic stem and progenitor cells have been used as an ex vivo gene therapy vehicle for kidney gene delivery, highlighting their ability to differentiate into macrophages within the kidney, forming tunneling nanotubes that can deliver genetic material and organelles to adjacent kidney cells, even across the basement membrane to target the proximal tubular cells. As gene therapy technologies continue to advance and our understanding of kidney biology deepens, there is hope for patients with genetic kidney disorders to eventually avoid kidney transplantation.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Khare V, Cherqui S. Targeted gene therapy for rare genetic kidney diseases. Kidney Int. 2024. PMID: 39222842. doi:10.1016/j.kint.2024.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。